Ekso Bionics (EKSO)

Executive Summary

Ekso Bionics is a leader in powered exoskeleton technology, serving medical rehabilitation, personal mobility, and industrial augmentation markets. Its flagship devices, such as the EksoNR and EksoUE, are used in over 300 rehabilitation centers globally to help patients with neurological conditions regain mobility. The company also develops the EksoVest for industrial workers to reduce fatigue and injury. With a focus on expanding indications and commercial partnerships, Ekso is positioned for growth as exoskeleton adoption accelerates in healthcare and manufacturing sectors. Recent revenue growth and gross margin improvements underscore operational progress, though the company remains unprofitable and faces competition from larger players like ReWalk and Hocoma. Key upcoming catalysts include FDA clearance for a next-generation rehabilitative exoskeleton optimized for stroke patients, a major industrial contract for its EksoVest product, and initiation of a pivotal clinical trial for a spinal cord injury personal mobility device. Successful execution on these fronts could drive stock re-rating and revenue acceleration, but regulatory and adoption risks persist. Overall, Ekso Bionics offers a high-risk, high-reward opportunity in the emerging exoskeleton market, with a conviction score reflecting balanced potential and challenges.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance of next-gen EksoNR for stroke rehabilitation70% success
• Q3 2026Major industrial partnership for EksoVest in logistics60% success
• Q1 2027Pivotal trial enrollment completion for spinal cord injury device50% success